Int Ophthalmol (2018) 38:1193–1204 https://doi.org/10.1007/s10792-017-0582-7 ORIGINAL PAPER Treatment of patients with neurotrophic keratitis stages 2 and 3 with plasma rich in growth factors (PRGF-Endoret) eye-drops . . . Ronald Mauricio Sanchez-Avila Jesus Merayo-Lloves Ana Cristina Riestra . . . Luis Fernandez-Vega Cueto Eduardo Anitua Leire Begona Francisco Muruzabal Gorka Orive Received: 26 August 2016 / Accepted: 5 June 2017 / Published online: 15 June 2017 Springer Science+Business Media B.V. 2017 Abstract and Visual Analogue Scale (VAS) were also evaluated Purpose To provide preliminary data about efﬁcacy before and after treatment with PRGF. The inﬂuence and safety of plasma rich in growth factors (PRGF) of some patients’ clinical variables on results was eye-drops in neurotrophic keratitis (NK) and to assessed. Safety assessment was also performed analyze the possible inﬂuence of certain variables on reporting all adverse events. treatment outcomes. Results Thirty-eight treated eyes in a total of thirty- Methods This retrospective study included patients one patients were evaluated, of which ﬁve cases had no with stages 2–3 of NK treated with PRGF eye-drops. prior response to autologous serum treatment. Most Primary endpoint was the resolution time of corneal cases (97.4%) achieved the complete resolution of ulcer defect. Outcome measures including
International Ophthalmology – Springer Journals
Published: Jun 15, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera